Fluorescence
In Situ Hybridization

Fluorescent in situ hybridization (FISH) and the related in situ hybridization (ISH) technologies provide complementary genomic information to NGS, NanoString, qPCR, and ddPCR techniques. FISH/ISH add spatial context that can be used to identify aberrant DNA and/or RNA molecules that are difficult to detect by other methods.

These techniques can also reveal localized gene expression differences that studies on bulk cells cannot provide, and which can be used to identify cell types, such as the makeup of the tumor microenvironment, or aberrant cell processes in specific regions of tissue. Precision develops state-of-the-art FISH and ISH assays to detect abnormalities in a range of tissues, including hematological and solid organ tumors.

Identify cytogenetic abnormalities and view spatial gene expression

Understand the spatial biology and cytogenetic status of your preclinical and clinical trial samples
Our FISH capabilities

Precision’s fluorescence in situ hybridization service enables the detection of cytogenetic abnormalities at the single cell level.

  • FISH in CTCs, CECs, FFPE, frozen tissue, and bone
  • Detect cellular genetic aberrations: multiploidy, translocations, amplifications or deletions
  • Custom FISH probe design services
  • Commercially available FISH assays
  • Proprietary disease-specific FISH panels
Our ISH capabilities

In addition to examining changes in DNA by FISH, Precision for Medicine is also able to measure spatial gene expression using ACD’s RNAscope ISH assays and technology. This platform enables sensitive gene expression imaging at the single-cell level, and can be single-plex, multi-plex, and dual ISH-ICH.

We can implement commercially available or custom RNA ISH targets.

FISH on circulating tumor cells (CTCs) in non-small-cell lung cancer

Cytogenetic analysis of CTCs often provides information regarding diagnosis, prognosis and therapeutic surveillance of cancer patients. At Precision we have developed DNA FISH assays to cytogenetically analyze CTCs after enrichment from patient whole blood.

Our standard workflow is to first isolate CTCs using ApoStream, followed by analysis. Through sequential processing and analysis we can also identify genetic aberrations in specific CTC phenotypes.

Global reach, multi-site support

Our FISH/ISH assay services support preclinical and clinical research, including multi-site studies, conducted anywhere in the world.

Working with Precision

Precision’s specialty lab scientists take a collaborative and consultative approach to projects and can provide recommendations on biomarker assay strategies and implementation. Services can be provided individually or as part of a comprehensive therapeutic development package including biomarker assays and clinical trials.

Related services

NGS

We offer NGS services including RNA-seq, whole exome sequencing, and targeted DNA/RNA sequencing services. NGS can be especially powerful when paired with our liquid biopsy technology, ApoStream.

ApoStream – CTC and Rare Cell Capture For Liquid Biopsy

ApoStream enables antibody-free isolation and concentration of target cells in liquid biopsy samples, enabling analysis of CTCs and other rare and low concentration components using methods like mIF, FISH, and genomic analyses.

Multiplex Immunofluorescence

We offer automated multiplex immunofluorescence (mIF) services that enable quantitative visualization of up to 9 markers in tissue and liquid biopsies, and individual cells. mIF can be integrated with other methods including co-analysis using FISH/ISH.

Discuss your project requirements

Whether you know exactly the type of immune monitoring approach you need or would like expert support with project design, we can deliver.

Discuss your project requirements

Whether you know exactly the type of immune monitoring approach you need or would like expert support with project design, we can deliver.

Explore other areas of expertise